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TRICYCLlC ANTIDEPRESSIVE~APOSSIBLE MODE OF ACTION
J. OFFERMEIER AND B. POTGIETER, Departmen/ of Pharmacology, po/chefstrool/7 Unil·ersity. po/chefs/room. TI'!
The catecholamines have important functions, probably
a neurotransmitters, in the central nervous system. Onc
of the catecholamines, dopamine, is possibly involved in
those systems regulating the locomotor activity of ani-
mals.]"
Dopamine is formed in certain parts of the central
nervous system, for instance in the substantia nigra of the
reticular formation, in relatively large amounts. The bio-
synthesis and metabolic inactivation of dopamine are
presented in Fig. I.








Fill. 2. Dopamine and its analogue al1lpl1c~aJl1ine.
(c) 'precursors' of dopamine like L-DOPA, which is
metabolized to dopamine in the central nervous
system, thereby causing an increase in the concen-
tration of dopamine; and
(d) drugs that inhibit the metabolic inactivation of
dopamine, like monoamine-oxidase inhibitors
(MAO inhibitors).
Some stimulant drugs presumably act by more than
one of the above mechanisms, for instance it has been
shown that methylphenidate (Rita:in) and phenmetrazine
(PrelUdin) act by mechanisms (a) and (b).' Many drugs
acting by the above mechanisms are or have been thera-
peutically used as 'central stimulants' or 'antidepressants'.
The role of dopamine as a neurotransmitter and the
mechanisms of action of the abovementioned groups of
drugs are schematically given in Fig. 3.
Dopamine is released from its protein-bound form
('stores') by nerve impulses along the presynaptic fibre.
The released dopamine diffuses via the cell membrane to
the synaptic cleft and acts as an agonist on specific do-
pamine receptors on the postsynaptic nerve cell, causing
a stimulus leading to an impulse along the postsynaptic
nerve fibre and, eventually, eliciting the effect-an in-
crease in locomotor activity. Some of the dopamine in the
synaptic cleft is presumably inactivated by the enzyme
catechol-O-methyltransferase «(OMT), and the rest
diffuses back into the presynaptic cell, possibly transported
across the cell membrane by an active transport mechan-
ism. In the presynaptic cell most of the dopamine is again
bound to protein, but a small amount is inactivated by
monoamine oxidase (MAO) in the mitochondria. There
is, apparently, an equilibrium between bound and free
dopamine in the presynaptic cell.
Experimental evidence for the role of dopamine in loco-
motor activity was mainly obtained on mice, rats and
guinea-pigs, using photocell activity cages to measure the
activity. It was shown that intraperitoneal injection of
amphetamine or cocaine in these animals gives an in-
crease of locomotor activity. After pretreatment of the















Fig. I. Tht.: biosynthesis and metabolic inactivation of dopamine.
Phenylalanine is converted to tyrosine and dihydroxyphenylalanine
(DOPA) by hydroxylation. Decarboxylation of DOPA, the direct
precursor of dopamine. leads to the formation of the latter substance.
Decarboxylalion presumably takes p:ace in the nerve-endings where
dopamine is ·stored'. Most of the formed dopamine is bound to
protein; in the bound form it cannot be broken down by the enzymt:
monoamine oxidase (MAO). MAO occurs in the mitochondria and
metabolizes unbound ('free') monoamines such as dopamine and
noradrenaline to the corresponding organic acids. Dopamine is released
from its bound form by nerve impulses and is then able to diffuse
into the synaptic cleft and act as an agonist on the dopamine receptors.











It is known that drugs causing a depletion of dopa-
mine in the central nervous system, such as reserpine.
etc., and drugs presumably acting as competitive antago-
nists on the dopamine receptors like chlorpromazine, etc.,
inhibit locomotor activity.·"o These groups of drugs may
be used as sedatives or 'major tranquillizers'. On the
other hand an enhancement of locomotor activity is ex-
hibited by drugs with the following mechanisms of
action:
(a) close structural analogues of dopamine, presuma-
bly acting as agonists directly on dopamine recep-
tors, like amphetamine, etc. ('direct action')
(Fig. 2);
(b) drugs causing a rapid release of bound dopamine,
thereby causing an increase in the dopamine con-
centration in the vicinity of the dopamine recep-
tors which are then stimulated by dopamine itself,
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Fig. 3. Schematic presentation of the role of dopamine and the mechanism of action of various stimulant and sedative drugs.
Fig. 4. StruclUral relationship between chlorpromazine and the tricyc:ic
antidepressives.
responsible for the uptake of noradrenaline into nerve
cells.'s,,, Tbe present investigation was carried out to
determine whether the mechani m of the tricyclic anti-
depressives in the central nervous system could be related
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mines in the central nervous system, amphetamine gives
tbe same increase in locomotor activity as before, but
cocaine has no effect. This indicates that amphetamine is
not dependent on the presence of dopamine for its action
and acts directly as an agonist on the dopamine receptors,
but that cocaine cannot give an effect in the absence of
dopamine and therefore presumably acts by a rapid re-
lease of dopamine from the protein-bound stores. Ampbe-
tamine may be called a 'direct dopaminergic drug' and
cocaine an 'indirect dopaminergic drug'.
The phenotbiazines like cWorpromazine and other com-
petitive antagonists of noradrenaline on the alpha-recep-
tors in the periphery all have a sedative action if they are
lipopbylic enougb to cross the blood-brain barrier.'"
The e compounds all antagonize the increase in locomotor
activity caused by amphetamine or cocaine and may be
a sumed to act by competitive antagonism on the dopa-
mine receptors, since dopamine and noradrenaline are
structurally very closely related.""'·
The tricyclic antidepressives are structurally clo ely
related to the phenothiazine, yet they appear to have
opposite effects on the central nervous ystem.
In experiments on isolated organs it could be shown
that the tricyclic antidepre ives ensitize the organ to
tbe action of noradrenaline"·H wberea the phenothia-
zine act as antagonists!' In higb concentrations, how-
ever, tbe tricyclic antidepressive act as competitive
antagonists of noradrenaline.'"'·' The sensitization ha been
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Fig. 50. Antagonism of the direct dopamincrgic drug methamphetamine by the tricyclic anli-
depres ive imipramine (Tofranil). M = methamphetamine 15 j.Ll11ol./kg.; J = imipramine
100 JLmol./kg.
Fig. 5b. Antagonism of the indirect dopammerglc drug chlorphen!ermmc by the
tricyclic antldepresslves amitriptyline (Tryptanol) and 1011pramme (TofraniI).
C = chlorphentermine 400 JLmol./kg.; J = imipramine JOO JLmol./kg.; A =
amitriptyline 100 tLmol./kg. Note in both cases the reduction of the effect of the







benzazepine derivatives with the side-chain in positIOns
other than I (such as opipramol, meclofenoxate, etc.) are
inactive as far a increased locomotor activity is concerned.
OISCUSSIO
The results indicate that the tricyclic antidepressant drugs
investigated have at least a dual mode of action in the
central nervous system. They exhibit an antagonistic
action towards dopaminergic drugs corresponding to the
antagonistic action of the phenothiazine derivatives. It i
assumed that this antagonism would correspond to a
sedative effect. It must be pointed out that the antagonistic
action of the iricyclic antidepressives is found at high
doses, much higher than doses needed for a similar anta-
gonism by, for instance, chlorpromazine. Since the tri-
cyclic antidepressants are structurally closely related to




Photocell activity cages were used to determine the
action of the drugs used on the locomotor activity of
Swi -Web ter mice. The cages measured 18 cm. x 65
cm. and had two parallel light beams, focused on two
cadium sulphide photo-electric cells, over the width of
the cage, 12·5 cm. from each end. The interruption of the
light beams was regi tered with cumu:ative recorders as
described in various publications.'· .. ·" The recorders re-
cord each interruption of a light beam by an upward
movement of 1 mm. of the recording pen on a sooted
kymograph drum. The drum rotated at 0·5 mm./min. and
every 30 seconds the pen returned to the zero position, so
that each vertical line on the registration represents the
number of light beam interruptions during a 30-second
period. The height of these lines is a measurement of the
locomotor activity of the animal.
Groups of 6 mice were used for
each experiment and all drugs were
injected intraperitoneally in isotonic
solutions. The concentrations of the
drugs in solution were such that 0·01
ml.1 G body-weight was always in-
jected. Control experiments with iso-
tonic sodium chloride injections were
done in all ca es.
In experiments where mice were
pretreated with an MAO inhibitor, the
compound pargyline (Eutonyl) was
used. Three injections, each of 500 ~t------------••••••
fJ.mol./kg., were given, at 12-hr inter- M
vals. The last of these 3 injections was
given I hr before treatment with the
tricyclic antidepressive.
RESULTS
one of the tricyclic antidepressants investigated
gave an increase of locomotor activity on its
own. These compounds, however, antagonize the
increase in locomotor activity caused by direct
or indirect dopaminergic drugs (Fig. 5).
The antagonistic effects as described above
correspond to the antagonistic effects produced
by phenothiazines like chlorpromazine. How-
ever, when an inhibitor of MAO is given before
administering one of the tricyclic compounds,
the latter causes an increase in locomotor activity
(Fig. 6). (The dose of the MAO inhibitor is such
that no increase in locomotor activity is found
when the inhibitor is given alone.) This increase
is not found with the phenothiazines.
The tricyclic antidepressants of which these
aspects were investigated are imipramine
ITofranil), desmethylimipramine (Pertrofan),
chlorimipramine (Anafranil), amitriptyline
(Tryptanol). nortriptyline (Aventyl), protripty-
line (Concord in). opipramol (Insidon), meclo-
fenoxate (Lucidril), dibenzepine ( overil) and
trimipramine (Surmontil). Of these the dimethyl
derivatives such as imipramine, amitriptyline and
e pecially chlorimipramine were very active in
causing an increase in locomotor activity of the
mice. These substances also acted more rapidly
than the other substances. The mono- and tri-
methyl derivatives are less active, whereas di-
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action for both these groups of drug may be ascribed to
the same mechanism. Ariens and Simonis" have po tu-
lated tbat competitive antagoni m of noradrenaline on
alpha-sympathetic receptors by chlorpromazine may be
ascribed to an affinity of the phenothiazine nucleus of
chlorpromazine to an 'additional' or 'acce ory' receptor
area. oradrenaline, a mentioned earlier, is also antago-
nized by the tricyclic antidepressives in higher concentra-
tions. There i a difference between the spatial structure
of the dibenzazepine nucleus of the tricyclic antide-
pressives and the phenothiazine nucleus of the pheno-
thiazine derivatives. If the nucleus i the main contri-
butory factor towards affinity on the accessory receptor
area it seems likely that for affinity to the alpha-receptor
of noradrenaline as well as for affinity to the dopamine




Fig. 6. Increase in locomotor activity caused by the tricyclic anti-
depressive imipramine (Tofranil) after pn::treatmcnt with the MAO
inhibitor pargyline (EutonyJ). Tote that a similar incrca~e is not
produced by the phenothiazine compound chlorpromazine. P = the
last injection of pargyline 500 pJTIol./kg.; J = imipramine 100
P.11101. kg.; CP = chlorpromazine 7-5 JlOlOI. kg.
Although the tricyclic antidepressant drugs do not
cause an increase in locomotor activity on their own. unlike
the other groups of antid::pressant drugs mentioned
earlier, tbey cause a ubstantial increase in the loco-
motor activity of the animals after pretreatment with an
inhibitor of MAO (Fig. 6). Reserpine. which is known to
cau e a depletion or slow relea e of d pamine from its
stores, also causes an increase in lo:omotor activity after
pretreatment with an inhibitor of MAO, since, under
these circumstances, the slowly released dopamine is not
broken down by MAO and the increase of the dopamine
concentration in the ynaptic cleft i large enough to
cause an increase in locomotor activity.'
The tricyclic antidepressives. however. are unable to
deplete the dopamine tores like reserpine doe when
given at regular intervals 0 er a period of time. Thi i
shown by the fact that the effect produced by indirect
dopaminergic is not altered by pretreatment with the
antidepressives in this way. It seems, therefore, that if
the tricyclic antidepressive act by releasing dopamine
lowly from it store, the mechanism of release i dif-
ferent from that exhibited by reserpine.
A second probable mechanism of action to be con-
sidered is an inhibition of re-uptake in the nerve ending,
as has been described for the tricyclic antidepressives in
sympathetic nerve endings."'" If this is the primary
mechanism of action. one would expect a strong potentia-
tion of the indirect dopaminergic drugs in the presence
of the tricyclic antidepressives, since the concentration of
dopamine in the synaptic cleft would then be increased
by the blockade of the re-uptake mechanism. Such a poten-
tiation, however, does not take place. Another finding not
favouring this mechanism of action is that the tricyclic
amidepres ives increase locomotor activity after inhibition
of MAO. The enzyme MAO is found in the nerve cell a
such and a blockade of the re-uptake of released dopa-
mine into the nerve cell by a tricyclic antidepres ive
would therdore rather tend to lessen the importance of
MAO. The fact that inhibition of MAO is a prerequisite
for an increase in locomotor activity by the tricyclic
antidepressives tends to support the view that the latter
compounds act by liberating dopamine from its stores.
Since the tricyclic antidepressives do not cause an in-
crease in locomotor activity when given alone, it appear-
that the liberation of dopamine is not ery fast and that
MAO can cope with the inactivation of the liberated
amine. On.::e MAO is inhibited. however, the concentra-
tion of unbound dopamine in the presynaptic nerve cell
b::comes so high that dopamine diffuses into the synaptic
c:eft. causing an increase in locomotor activity.
S MMAI,V
The tricyclic antidepressives seem to have at least a dual mode
of action in the central n~rvous syst~m. They antagonize the
effect of dopa'11inergic drugs. but aft~r pretreatment with
MAO inh:b:tors they cause an increase in locomotor activity.
The increase in locomotor activity is presumably caused by
a slow lib~ration of dopamine fro:n its protein-bound stores.
The mechanism of this liberation does not appear to be the
same as the liberation c~used by reserpine.
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A COMPARATIVE STUDY OF THE AVAILABILITY OF SULPHAFURAZOLE FROM COM·
MERCIAL BRANDS OF SULPHAFURAZOLE TABLETS
A. P. GOD SE SAD M. C. B. VA OUDTSHOORN, Department of Pharmaceutics, Po/chefs/room University,
Potchefstroom, Tvl
M---~Um
The following differential equations are propo ed to
de cribe Ihe model:
A ---Iag .----7) B
k i, I
PHARl\.1ACOKINETIC MODEL
The following pharmacokinetic model is presented to
describe the kinetics of sulphafurazole absorption, meta-
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life for acetylsul- B
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Theoretical A



























TABLE I. ANALYTICAL DATA, AND RATE A D OTHER co STANTS











- = klA - (k,B + k,B)
dt








le has been shown by everal authors that the physical
propertie of a drug, uch a particle size, solubility, dis-
olution rate, etc., may have an effect on the biological
availability of the drug.]-· In the course of a tudy aimed
at the determination of the effect of variables in the
formulation of ulphafurazole tablets on the biological
availability of this drug, pharmacokinetic parameters for
sulphafurazole were determined as part of the preliminary
investigation, using 4 brand of local commercially
available sulphafurazole tablets.
The tablets were administered after an alkali load in
order to eliminate diurnal fluctuation in urinary pH.
